Our work is featured in HCPLive showcasing how an #EEG biomarker can predict placebo response in #MDD clinical trials. These findings highlight the applications of this biomarker in #ClinicalTrials and potential to advance #PrecisionPsychiatry: bit.ly/4iIyp1K

Today, we reported our Q1 2025 financial results and key business highlights. Read more in our press release here: investors.altoneuroscience.com/news/news-deta… $ANRO

Today, our CEO, Amit Etkin, will participate in a panel discussion moderated by Ron Leuty at the Bay Area Biotech Forum, presented by San Francisco Business Times. Learn more about the event here: bizjournals.com/sanfrancisco/e… #SFBTbiotech

Today we announced the acquisition of a novel dopamine agonist portfolio, adding a late-stage readout in treatment resistant depression within our current cash runway. We’re excited for the opportunity to advance this approach! Read more: investors.altoneuroscience.com/news/news-deta…

📣A Parkinson’s drug, #pramipexole, shows promise for #treatmentresistantdepression. In an @oxpsych led and National Institute for Health and Care Research supported trial, patients saw major symptom relief by week 12—with effects lasting a year. Read more: tinyurl.com/pramipexoleTRD

We’re excited to highlight that data from the PAX-D study evaluating pramipexole in patients with treatment-resistant depression (TRD) were published online in The Lancet Psychiatry. Results from this study guided Alto’s acquisition of ALTO-207. Read more: investors.altoneuroscience.com/news/news-deta…

Congrats to the Oxford Psychiatry team, Mike Browning and the PAX-D investigators on a landmark finding demonstrating striking efficacy of pramipexole in TRD!

Important PAX-D publication today! I highlight the findings and how ALTO-207 builds on that success in the video below

It was a pleasure to speak with BiotechTV today at the NYSE 🏛!

LIVE on NYSE TV 🎙️ Hear top economic data from Eddie Ghabour. Amit Etkin of Alto Neuroscience shares how they are utilizing AI at NYSE hosted AI x Bio Summit. Plus, Accelerant celebrates its IPO $ARX! x.com/i/broadcasts/1…

Was a lot of fun sharing the Alto Neuroscience story and updates on the iconic floor of the NYSE 🏛. A lot of clinical readouts to come over the next two years!

Here's the link to the full interview on the NYSE 🏛 floor from last week at the AI x Bio summit. It was a pleasure to share what we are up to Alto Neuroscience! A lot of exciting potential ahead. tv.nyse.com/floor-talk/sea…

Last week, our CEO Amit Etkin joined #NYSEFloorTalk to share how Alto is advancing a new era of precision psychiatry and how we’re using #MachineLearning and #AI across our clinical-stage pipeline. Thank you, NYSE 🏛 for the opportunity to share our story: tv.nyse.com/videos/dr-amit…